CY1115863T1 - Ενωσεις τριαζολοπyριδινης - Google Patents
Ενωσεις τριαζολοπyριδινηςInfo
- Publication number
- CY1115863T1 CY1115863T1 CY20141100951T CY141100951T CY1115863T1 CY 1115863 T1 CY1115863 T1 CY 1115863T1 CY 20141100951 T CY20141100951 T CY 20141100951T CY 141100951 T CY141100951 T CY 141100951T CY 1115863 T1 CY1115863 T1 CY 1115863T1
- Authority
- CY
- Cyprus
- Prior art keywords
- triazolopyridine compounds
- compounds
- triazolopyridine
- medicaments
- formula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Abstract
Η εφεύρεση αφορά ενώσεις τριαζολοπυριδίνης του τύπου (I), όπου τα R1, R2, R3 και R4 είναι όπως ορίζονται στην περιγραφή και τις αξιώσεις, καθώς και με φυσιολογικώς αποδεκτά άλατα αυτών. Αυτές οι ενώσεις αναστέλλουν το PDE 10Α και μπορούν να χρησιμοποιηθούν ως φάρμακα.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10194014 | 2010-12-07 | ||
EP11791543.9A EP2649070B1 (en) | 2010-12-07 | 2011-12-05 | Triazolopyridine compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1115863T1 true CY1115863T1 (el) | 2017-01-25 |
Family
ID=45099086
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20141100951T CY1115863T1 (el) | 2010-12-07 | 2014-11-14 | Ενωσεις τριαζολοπyριδινης |
Country Status (30)
Country | Link |
---|---|
US (1) | US8349824B2 (el) |
EP (1) | EP2649070B1 (el) |
JP (1) | JP5932828B2 (el) |
KR (1) | KR20130128426A (el) |
CN (1) | CN103237803B (el) |
AR (1) | AR084152A1 (el) |
AU (1) | AU2011340685A1 (el) |
BR (1) | BR112013013912A2 (el) |
CA (1) | CA2816829C (el) |
CL (1) | CL2013001591A1 (el) |
CO (1) | CO6741154A2 (el) |
CR (1) | CR20130239A (el) |
CY (1) | CY1115863T1 (el) |
DK (1) | DK2649070T3 (el) |
EA (1) | EA022607B1 (el) |
EC (1) | ECSP13012667A (el) |
ES (1) | ES2520647T3 (el) |
HR (1) | HRP20141200T1 (el) |
IL (1) | IL225969A0 (el) |
MA (1) | MA35086B1 (el) |
MX (1) | MX2013006054A (el) |
PE (1) | PE20140226A1 (el) |
PL (1) | PL2649070T3 (el) |
PT (1) | PT2649070E (el) |
RS (1) | RS53677B1 (el) |
SG (1) | SG190305A1 (el) |
SI (1) | SI2649070T1 (el) |
UA (1) | UA109037C2 (el) |
WO (1) | WO2012076430A1 (el) |
ZA (1) | ZA201303811B (el) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2757883B1 (en) * | 2011-09-22 | 2021-01-13 | Merck Sharp & Dohme Corp. | Triazolopyridyl compounds as aldosterone synthase inhibitors |
US20140235667A1 (en) | 2011-09-22 | 2014-08-21 | Merck Sharp & Dohme Corp. | Imidazopyridyl compounds as aldosterone synthase inhibitors |
RU2620379C2 (ru) | 2012-02-09 | 2017-05-25 | Ф.Хоффманн-Ля Рош Аг | СПОСОБ ПОЛУЧЕНИЯ ПРОИЗВОДНЫХ 2-ФЕНИЛ[1,2,4]ТРИАЗОЛО[1,5-а]ПИРИДИНА |
BR112015017674A2 (pt) * | 2013-01-31 | 2017-07-11 | Hoffmann La Roche | compostos rádio marcados |
AU2014221799B2 (en) * | 2013-02-27 | 2017-09-28 | Mochida Pharmaceutical Co., Ltd. | Novel pyrazole derivative |
HUE032407T2 (en) | 2013-04-30 | 2017-09-28 | Hoffmann La Roche | Plasma catalyzed coupling of pyrazolamides |
EP3006444B1 (en) * | 2013-05-31 | 2017-09-27 | Nissan Chemical Industries, Ltd. | Heterocyclic amide compound |
WO2015006689A1 (en) | 2013-07-12 | 2015-01-15 | University Of South Alabama | Treatment and diagnosis of cancer and precancerous conditions using pde10a inhibitors and methods to measure pde10a expression |
EP3176168A4 (en) * | 2014-07-30 | 2018-05-02 | Mochida Pharmaceutical Co., Ltd. | Pyrazole derivative manufacturing method |
WO2016017711A1 (ja) * | 2014-07-30 | 2016-02-04 | 持田製薬株式会社 | ピラゾール誘導体の製造方法 |
WO2020021024A1 (en) * | 2018-07-26 | 2020-01-30 | Phenex Pharmaceuticals Ag | Substituted bicyclic compounds as modulators of the aryl hydrocarbon receptor (ahr) |
IL298713A (en) | 2020-06-05 | 2023-02-01 | Noema Pharma Ag | Use of a phosphodiesterase 10 inhibitor to treat Tourette syndrome |
CA3206573A1 (en) * | 2021-01-28 | 2022-08-04 | George GARIBALDI | Methods for the treatment of childhood-onset fluency disorder |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070032404A1 (en) | 2003-07-31 | 2007-02-08 | Bayer Pharmaceuticals Corporation | Methods for treating diabetes and related disorders using pde10a inhibitors |
TWI501965B (zh) | 2008-06-20 | 2015-10-01 | Lundbeck & Co As H | 作為pde10a酵素抑制劑之新穎苯基咪唑衍生物 |
-
2011
- 2011-12-01 US US13/308,588 patent/US8349824B2/en active Active
- 2011-12-05 UA UAA201308329A patent/UA109037C2/uk unknown
- 2011-12-05 AU AU2011340685A patent/AU2011340685A1/en not_active Abandoned
- 2011-12-05 SI SI201130309T patent/SI2649070T1/sl unknown
- 2011-12-05 ES ES11791543.9T patent/ES2520647T3/es active Active
- 2011-12-05 KR KR1020137016458A patent/KR20130128426A/ko not_active Application Discontinuation
- 2011-12-05 EA EA201390799A patent/EA022607B1/ru not_active IP Right Cessation
- 2011-12-05 PE PE2013001371A patent/PE20140226A1/es not_active Application Discontinuation
- 2011-12-05 WO PCT/EP2011/071685 patent/WO2012076430A1/en active Application Filing
- 2011-12-05 DK DK11791543.9T patent/DK2649070T3/da active
- 2011-12-05 PL PL11791543T patent/PL2649070T3/pl unknown
- 2011-12-05 JP JP2013542480A patent/JP5932828B2/ja active Active
- 2011-12-05 BR BR112013013912A patent/BR112013013912A2/pt not_active Application Discontinuation
- 2011-12-05 CA CA2816829A patent/CA2816829C/en active Active
- 2011-12-05 RS RS20140574A patent/RS53677B1/en unknown
- 2011-12-05 AR ARP110104533A patent/AR084152A1/es unknown
- 2011-12-05 MX MX2013006054A patent/MX2013006054A/es active IP Right Grant
- 2011-12-05 CN CN201180057674.XA patent/CN103237803B/zh active Active
- 2011-12-05 PT PT117915439T patent/PT2649070E/pt unknown
- 2011-12-05 EP EP11791543.9A patent/EP2649070B1/en active Active
- 2011-12-05 SG SG2013037676A patent/SG190305A1/en unknown
-
2013
- 2013-04-25 IL IL225969A patent/IL225969A0/en unknown
- 2013-04-25 CO CO13105814A patent/CO6741154A2/es active IP Right Grant
- 2013-05-22 CR CR20130239A patent/CR20130239A/es unknown
- 2013-05-24 ZA ZA2013/03811A patent/ZA201303811B/en unknown
- 2013-06-04 CL CL2013001591A patent/CL2013001591A1/es unknown
- 2013-06-06 EC ECSP13012667 patent/ECSP13012667A/es unknown
- 2013-06-20 MA MA36027A patent/MA35086B1/fr unknown
-
2014
- 2014-11-14 CY CY20141100951T patent/CY1115863T1/el unknown
- 2014-12-11 HR HRP20141200AT patent/HRP20141200T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1115863T1 (el) | Ενωσεις τριαζολοπyριδινης | |
CY1119953T1 (el) | Yποκατεστημενες πυριδοπυραζινες ως προτυποι syk ανοστολεις | |
CY1122585T1 (el) | Συνδυασμοι που περιλαμβανουν παραγωγα 5-φαινοξυ-3η-πυριμιδιν-4-ονης και η χρηση αυτων για την προφυλαξη ή αγωγη λοιμωξης απο ηiv | |
CY1114764T1 (el) | Παραγωγα προλινης ως αναστολεις καθεψινης | |
CY1115945T1 (el) | Παραγωγα πυραζολοκινολινονης, η παρασκευη τους και η θεραπευτικη τους χρηση | |
CY1120031T1 (el) | Αποπτωτικοι υποκινητες ν-ακυλοσουλφοναμιδης | |
CY1116120T1 (el) | Παραγωγα ιμιδαζοπυριδινης ή ιμιδαζοπυριμιδινης ως αναστολεις φωσφοδιεστερασης 10α | |
CY1117878T1 (el) | Πυριδινo-2-αμιδια χρησιμα ως αγωνιστες του cb2 | |
CY1118735T1 (el) | Παραγωγα βενζιμιδαζολο-προλινης | |
CY1119049T1 (el) | Υποκατεστημενα πυρρολιδινο-2-καρβοξαμιδια | |
CY1114793T1 (el) | Παραγωγα αμινοπυραζολιου | |
CY1117147T1 (el) | Παραγωγα [1,2,3]τριαζολο[4,5-d]πυριμιδiνης ως αγωνιστες του κaνναβινοειδους υποδοχεα 2 | |
CY1117956T1 (el) | N3-αντικατεστημενα-n1-sulfonyl-5-fluoropyrimidinone παραγωγα | |
CY1116984T1 (el) | ΠΑΡΑΓΩΓΑ [1,2,3]ΤΡΙΑΖΟΛΟ[4,5-d]ΠΥΡΙΜΙΔΙΝΗΣ ΩΣ ΑΓΩΝΙΣΤΕΣ ΥΠΟΔΟΧΕΑ ΚΑΝΝΑΒΙΝΟΕΙΔΩΝ 2 | |
CY1117105T1 (el) | Ενωσεις πυριδαζινονης και χρηση τους ως αναστολεις του daao | |
CY1118950T1 (el) | Νεα παραγωγα πυραζολιου | |
CY1119619T1 (el) | Παραγωγα πυριδιν-4-υλιου | |
CY1115301T1 (el) | Παραγωγα ισοξαζολης και η χρηση τους ως ενισχυτων μεταβοτροπικου υποδοχεα γλουταμικου | |
CY1118662T1 (el) | Νεες δικυκλικες πυριδινονες | |
NI201200191A (es) | Derivados de indolizina, su procedimiento de preparación y su aplicación en terapéutica | |
CR20150250A (es) | Nuevos derivados de piridina | |
CY1114759T1 (el) | Παραγωγα πυριδιν-4-υλι0υ ως s1p1/edg1 αγωνιστες | |
CY1118593T1 (el) | Πρωτοτυπα παραγωγα πυραζινης | |
ECSP109856A (es) | Derivados de oxadiazol y su uso como potenciadores de los receptores metabotrópicos de glutamato - 842 | |
UA116395C2 (uk) | ПОХІДНІ ТРИАЗОЛ[4,5-b]ПІРИМІДИНУ |